C3N-02289
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 73.73305955
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.500
- HYPOXIA+0.500
- TNFA_SIGNALING_VIA_NFKB+0.470
- MYOGENESIS+0.410
- APICAL_JUNCTION+0.380
- COAGULATION+0.330
- WNT_BETA_CATENIN_SIGNALING+0.330
- APOPTOSIS+0.290
- P53_PATHWAY+0.270
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- PROTEIN_SECRETION-0.320
- MYC_TARGETS_V1-0.290
- INTERFERON_GAMMA_RESPONSE-0.250
- PEROXISOME-0.220
- FATTY_ACID_METABOLISM-0.190
- E2F_TARGETS-0.180
- BILE_ACID_METABOLISM-0.170
- G2M_CHECKPOINT-0.170
- OXIDATIVE_PHOSPHORYLATION-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02963 | — | cohortSQ1 | 0.824 |
| 2 | MNG721 | — | — | 0.817 |
| 3 | BS_RXN5T5YT | Diffuse intrinsic pontine glioma | — | 0.801 |
| 4 | BS_J8VX4D17 | EPN | Posterior Fossa EPN | 0.800 |
| 5 | 82992 | EPN | Supratentorial EPN | 0.798 |
| 6 | TCGA-CR-6474-01A-11R-1873-07 | — | — | 0.798 |
| 7 | C3L-02660 | — | cohortSQ1 | 0.795 |
| 8 | C3N-02339 | — | cohortSQ1 | 0.795 |
| 9 | TCGA-BL-A5ZZ-01A-31R-A30C-07 | — | — | 0.795 |
| 10 | TCGA-90-6837-01A-11R-1949-07 | — | cohortSQ1 | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| HYPOXIA | 0.500 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |